Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals reported strong Q4 FY26 results with revenue up 10% to ₹642 million and PAT surging 31% to ₹88 million. Full-year FY26 revenue grew 7% to ₹2,872 million while PAT jumped 19% to ₹446 million. The company posted EBITDA of ₹609 million with 21.2% margin for FY26. Cash position strengthened to ₹191 crore, up ₹45 crore during the year. The board approved a ₹40 crore buyback (16 lakh shares at ₹250 each) with promoters not participating, expected to improve ROCE from 22% to 25.7% and ROE from 16.2% to 18.9%. A 200% dividend (including 75% special dividend) totaling ₹26.2 crore was recommended. The company outperformed the IPM market, growing 12.2% versus industry growth of 8.6%, with top 10 brands driving 58% of revenues.
The strong profit growth, shareholder-friendly capital return actions (buyback and enhanced dividend), and healthy cash position signal solid operational performance and confidence in future prospects, which should be viewed positively by investors.